Definium Therapeutics Inc logo

Definium Therapeutics Inc

DFTX
Healthcare|Biotechnology|USA
$47.07
-1.37 (-2.83%)
Tangible Book
$2.49

Upcoming Data Readouts (3)

Aug 2026
Est. completion
P3Generalized Anxiety Disorder
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
NCT06809595n=245
Aug 2027
Est. completion
P2Autism Spectrum Disorder
A Phase 2A Trial of DT402 for Autism Spectrum Disorder
NCT07303907n=20
Sep 2027
Est. completion
P3Major Depressive Disorder
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
NCT07592689n=165

Awaiting Results (2)

Trials past primary completion date but still active — data readout may be imminent.

Jul 2026
P3
A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)
NCT06741228
May 2026
P3
A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)
NCT06941844

Recent Press Releases